Previous Article | Next Article 
Journal of Virology, August 1999, p. 7050-7055, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mass Determination of Rous Sarcoma Virus Virions by
Scanning Transmission Electron Microscopy
Volker M.
Vogt1,* and
Martha N.
Simon2
Section of Molecular Biology and Genetics,
Cornell University, Ithaca, New York 14853,1
and Department of Biology, Brookhaven National
Laboratory, Upton, New York 119732
Received 4 December 1998/Accepted 7 May 1999
 |
ABSTRACT |
The internal structural protein of retroviruses, Gag, comprises
most of the mass of the virion, and Gag itself can give rise to
virus-like particles when expressed in appropriate cells. Previously the stoichiometry of Gag in virions was inferred from indirect measurements carried out 2 decades ago. We now have directly determined the masses of individual particles of the prototypic avian retrovirus, Rous sarcoma virus (RSV), by using scanning transmission electron microscopy. In this technique, the number of scattered electrons in the
dark-field image integrated over an individual freeze-dried virus
particle on a grid is directly proportional to its mass. The RSV
virions had a mean mass of 2.5 × 108 Da,
corresponding to about 1,500 Gag molecules per virion. The population
of virions was not homogeneous, with about one-third to two-thirds of
the virions deviating from the mean by more than 10% of the mass in
two respective preparations. The mean masses for virions carrying
genomes of 7.4 or 9.3 kb were indistinguishable, suggesting that mass
variability is not due to differences in RNA incorporation.
 |
TEXT |
The assembly of retroviruses appears
deceptively simple. A single protein, the product of the gag
gene, organizes the internal structure of the virion. Expression of the
Gag protein, even in the absence of other viral proteins such as Pol
and Env, leads to budding of virus-like particles from the plasma
membrane of the cell. In a process called maturation, the viral
protease proteolytically processes Gag late in the budding process to
yield the several internal structural proteins that have been known for
many years to comprise the bulk of the protein mass of the virion
(7, 8, 12, 35, 38). The remaining protein mass is accounted for by products of the env gene and the pol gene,
as well as by minor amounts of host cell proteins. Several particular
host proteins have been documented in retroviruses (2, 13, 19, 20, 27, 36), but each comprises no more than a few percent of the
total protein mass. The nature of the protein-protein interactions, protein-lipid interactions, and protein-RNA interactions that occur during assembly remains incompletely understood, and the underlying principles that determine the stoichiometry of Gag in
the virion are unknown. In human immunodeficiency virus type 1 (HIV-1)
(14) and in murine leukemia virus (MLV) (40), and thus probably in all retroviruses, mature and immature virions are
somewhat heterogeneous in size as visualized by cryo-electron microscopy (cryo-EM). Neither mature nor immature virions show evidence
of icosahedral symmetry, in contrast to common pictoral representations
of retroviruses. Small deletions in Rous sarcoma virus (RSV) capsid
protein (CA) (18) or HIV p6 (15, 16) can lead to
virus-like particles that are grossly heterogeneous in size but that
nevertheless appear to bud normally from the plasma membrane.
An understanding of retrovirus structure requires knowledge of the
number of Gag molecules in a virion. The most straightforward method to
estimate stoichiometry is based on the mass of the particle and the
percentage of the mass that is due to Gag protein. The dry mass of
retrovirus particles has often been said to be composed of about
two-thirds protein, one-third lipid, and a few percent RNA. The viral
lipid, compared with total cellular lipids, is enriched for cholesterol
and sphingomyelin (1, 28). Perhaps the first attempt to
quantify retroviral mass was reported 40 years ago for avian
myeloblastosis virus (AMV) (4), a favorite system in early
studies because of the vast numbers of particles shed into the blood of
infected chicks. The ratio of particles, as determined by EM, to the
combined masses of protein, lipid, and RNA led to the retroviral mass
estimate of about 4.5 × 108 Da per particle. Perhaps
the most careful estimate for the number of Gag molecules in an avian
retrovirus particle was derived some 25 years ago (35) and
was based on the measured value of 0.038 for the ratio of total RNA to
protein in virions, on the measurement of the percentage of protein
comprising each Gag protein, and on the assumption that each virion
carries one genomic RNA molecule of 1.0 × 107 Da plus
0.4 × 107 Da of tRNA. The authors concluded that an
AMV virion contains 4,100 molecules of CA (then called p27), 3,600 molecules of matrix protein (MA) (p19), 5,800 molecules of nucleocapsid
protein (NC) (p12), and 5,500 molecules of protease (PR) (p15). A
somewhat earlier estimate for the very closely related avian retrovirus MC29 was 3,000 molecules of CA (then called gs1), 1,800 molecules of MA
(gs2), 2,000 molecules of NC (gs4), and 3,000 molecules of PR (gs3)
(12). It is important to note that both of these studies
predated the discoveries that retroviruses have diploid genomes and
that the internal structural proteins are derived by proteolytic
processing of a single protein, later called Gag. From what is now
known, the ratio of RNA to protein in virions used in the study
published in reference 35 was too high and the
amount of total RNA was too low.
We decided to reinvestigate the mass of RSV virions by using the
scanning transmission electron microscope (STEM) at Brookhaven National
Laboratory. The STEM is capable of examining individual unstained,
unshadowed freeze-dried particles and determining their masses. Virus
particles in solution are adsorbed to a thin carbon support film on an
EM grid. They are then extensively washed, quick-frozen, freeze-dried
overnight, and transferred to the microscope for viewing. Tobacco
mosaic virus (TMV) is used as an internal control and calibrator on
each grid. The STEM operates in a dark-field mode, and a 40-kV electron
probe focussed at 0.25 nm scans an image of 512 by 512 pixels. At each
point, the number of scattered electrons, collected by two annular
detectors, is recorded digitally. The number of scattered electrons is
directly proportional to the mass thickness at that point. The mass of
a particle is determined by summing the number of scattered electrons
over an entire particle after subtracting the support film
contribution. The mass determined for large particles such as viruses
should be accurate to within a few percent. STEM analysis, which has
been reviewed recently (39), has been used frequently to
characterize the masses of nonenveloped viruses but until now has been
applied to only one enveloped virus, vesicular stomatitis virus (VSV)
(37). The data obtained in that classic study led to the
accepted stoichiometry of virion proteins in VSV.
Preparation and biochemical analysis of virus stocks.
Two
molecular clones that differ in size by 1.9 kb were used to derive the
stocks of virus used in this study. The plasmid pRCASBP is a DNA clone
of the Schmidt-Ruppin A strain of RSV with the original pol
gene replaced by that of the closely related Bryan strain of RSV and
with the original src gene deleted and replaced by a short
synthetic linker with a ClaI restriction site (25,
26). The plasmid pRCASBP-AP is identical except for the insertion
of the human placental alkaline phosphatase gene in the ClaI
site (10a, 11). Virus infections were initiated by transfection of turkey embryo fibroblasts, and after the infection had
spread to all of the cells, medium containing virus was collected at
24-h intervals. Parallel plates of turkey embryo fibroblasts were
continuously labeled with [14C]glycine (6 µCi/ml, 60 µCi/µmol), [14C]leucine (2.5 µCi/ml, 30 µCi/µmol), or [3H]mannose (100 µCi/ml) or were
pulse-labeled for 30 min with [35S]methionine (500 µCi/ml) and then grown in normal, unlabeled medium for 20 h. The
media for amino acid labeling were prepared without the respective
radioactive amino acids. For each set of plates, the collected medium
was centrifuged at 5,000 × g to remove debris and
filtered through a 0.45-µm-pore-size filter, and then the unlabeled
or labeled virus was collected by centrifugation for 2.5 h at
25,000 rpm (SW28 rotor) through a 5-ml cushion of 15% sucrose in virus
suspension buffer (VSB; 10 mM Tris HCl [pH 7.5], 50 mM NaCl, 1 mM
EDTA). The supernatant was removed by aspiration, the pellet was
resuspended in VSB plus 5% sucrose, and then the virus was purified
further by isopycnic centrifugation for 2 h at 50,000 rpm (TLS55
swinging-bucket rotor) in a 2-ml gradient of 15 to 50% (wt/wt) sucrose
in VSB. The visible band of virus was collected and diluted fivefold in
VSB, and the virus particles were collected again by centrifugation.
The yield of RCASBP was about twice that of RCASBP-AP at all stages of
purification, for the unlabeled as well as all of the labeled
preparations. Parallel samples of labeled and unlabeled virus were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Coomassie staining, fluorography, and PhosphorImager analysis.
The purified virus showed a pattern of stained polypeptides like that
commonly reported for the avian sarcoma and leukosis viruses (24,
34, 38) (Fig. 1). The profiles for
RCASBP (lanes 4 and 6) and RCASBP-AP (lanes 3 and 5) were identical, as
expected, with virus samples that had been purified by pelleting from
the medium (lanes 5 and 6) being only slightly less pure than samples that in addition had been centrifuged to equilibrium in sucrose gradients (lanes 3 and 4). The display of polypeptides was nearly identical to that for AMV used as a standard (lane 2). The Gag proteins
CA, MA, NC, PR, and p10 accounted for the bulk of the stained proteins,
with NC, PR, and p10 comigrating on the minigels used in these
experiments. Proteins labeled with radioactive amino acids and
visualized by fluorography yielded the same pattern of bands, as shown
in Fig. 1 for [35S]methionine (lane 7),
[14C]glycine (lanes 8 and 9), and
[14C]leucine (lane 10). The next most abundant proteins
after Gag were the Env surface and transmembrane proteins (SU and TM,
respectively) (8, 30), as determined by their labeling with
[3H]mannose (lane 11). SU migrated faster than implied by
the standard nomenclature (gp85) for avian SU proteins, as was reported
already many years ago for this strain of RSV (8),
presumably due to the presence of fewer glycosylation sites than in the
SU proteins of other strains. Barely evident bands corresponding to the
(65-kDa) and
(93-kDa) polypeptides of reverse transcriptase bracketed the SU band, and a band corresponding to integrase (IN) (32 kDa) was visible in the same region as TM. These pol gene products are expected to be present at a stoichiometry of about 1:20
compared with Gag (17). A minor band corresponding to a molecular mass of 40 kDa is likely to be cellular actin, which is known
to be incorporated into some retroviruses in small amounts (20) and to interact with Gag (29).

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Gel analysis of viral proteins. Samples of purified
unlabeled and radioactively labeled RCASBP and RCASBP-AP virus were
analyzed by SDS-PAGE on three separate minigels. The gel on the left
(15% polyacrylamide) (lanes 1 to 6) was stained with Coomassie blue
(approximately 20 µg of protein per lane). The gel in the middle
(17.5% polyacrylamide) (lanes 7 to 10) and the gel on the right
(17.5% polyacrylamide) (lanes 11 and 12) were submitted to
fluorography at 70°C after being impregnated with 1 M sodium
salicylate and dried (4,000 to 13,000 cpm per lane for 35S
and 14C; 50,000 cpm per lane for 3H). The virus
preparations shown in lanes 5, 6, and 11 were obtained by pelleting
virus particles from the medium, while the remainder of the
preparations were further purified by isopycnic banding of the pelleted
virus particles. The sample in lane 12 was used as a parallel standard
on the same gel as lane 11 to mark the positions of the nonglycosylated
proteins. All gels were purposely overloaded to better visualize minor
proteins other than Gag. Lane 1, Rainbow marker proteins (Amersham);
lane 2, AMV from leukemic chick plasma; lane 3, RCASBP-AP; lane 4, RCASBP; lane 5, RCASBP-AP; lane 6, RCASBP; lane 7, [35S]methionine-labeled RCASBP; lane 8, [14C]glycine-labeled RCASBP-AP; lane 9, [14C]glycine-labeled RCASBP; lane 10, [14C]leucine-labeled RCASBP; lane 11, [3H]mannose-labeled RCASBP; lane 12, [14C]glycine-labeled RCASBP.
|
|
Quantitation of the 14C-labeled proteins by PhosphorImager
analysis showed that the sum of all Gag proteins represented 78% of
the total protein in the gel lane, for both [14C]glycine-
and [14C]leucine-labeled RCASBP. For this purpose, Gag
proteins were operationally defined as the sum of all radioactive
material that migrated with a mobility equal to or faster than that of
CA, including material at the buffer front. This value thus should
include not only CA, MA, NC, PR, and p10 but also the peptides p2a, p2b
(22, 24), and SP (23), which also are cleaved
from Gag. This definition of Gag leaves out the variable amount of
incompletely processed MA molecules with the attached downstream p2 and
p10 domains, which migrate above the CA band. On the other hand, this
definition of Gag proteins is an overestimate to the degree that
low-molecular weight cellular proteins
for example, ubiquitin
(27)
are included. The Env protein SU represented 4.4 and
3.8% of total protein for glycine-labeled and leucine-labeled RCASBP,
respectively. SU was operationally defined as the total amino
acid-labeled material that migrated with the [3H]mannose
marker band run on parallel lanes. The Env protein TM could not be
quantitated reliably, since IN and the partially processed MA form
migrate in the same part of the gel. A smear of cellular polypeptides
extended throughout the lane. We assume that much of this material is
incorporated into virions, since preliminary experiments with
subtilisin treatment of the virus preparation (20) did not
result in a significant reduction of the smear.
Analysis by STEM.
Portions of the sucrose gradient-banded
RCASBP and RCASBP-AP virus preps in VSB were used to prepare grids for
STEM. A 3-µl aliquot was injected into a drop of buffer and allowed
to adsorb for 1 min to the 2- to 3-nm-thick carbon support film (to
which TMV had previously been adsorbed). The grids were washed
extensively, blotted to a thin layer of liquid, quick frozen,
freeze-dried overnight, and then transferred under vacuum to the STEM
for viewing. An image of 512 by 512 pixels was acquired by recording
the number of scattered electrons at each point. A representative
dark-field electron micrograph is shown in Fig.
2. Six round RSV virions can be seen
along with two long, thin TMV particles. Some smaller contaminants are
visible in the background. The mass of each particle was determined by
summing the number of scattered electrons over an entire particle,
subtracting the background from the support film (determined in clear
areas between particles), and using TMV on the same grid as a
microscope calibrator (39). The results yielded a wide
distribution of particle masses, with means of 2.62 × 108 Da (standard deviation = 0.65; n = 77) for RCASBP and 2.44 × 108 Da (standard
deviation = 0.34; n = 66) for RCASBP-AP (Fig.
3). We consider these two mean masses to
be statistically indistinguishable, although for unknown reasons the
distribution of masses was wider for the virus carrying the smaller
genome. Since the accuracy and precision of the STEM measurements are
expected to be better than 5%, the RSV virions analyzed here are
distinctly heterogeneous. From recent cryo-EM studies it is known that
HIV-1 (14) and MLV (40) also are heterogeneous in
size. The mean RSV mass is very similar to that measured by STEM for
VSV, 2.65 × 108 Da, in the classic study by Thomas et
al. (37).

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 2.
Visualization of virus particles by STEM. This
dark-field electron micrograph shows a field with six RCASBP-AP
particles. The three indicated by arrowheads were used for mass
measurements as described in the text. (The other three could not be
used because one is not fully visible, one is too close to a TMV, and
one is too close to a contaminating mass.) The arrows point to TMV
particles (used as an internal control). Some smaller contaminants can
be seen in the background; it is possible that these are similar to
microvesicles described by Ott et al. (20). The full scale
of the micrograph is 1.024 µm.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Distribution of virus particle mass. The masses of
RCASBP and RCASBP-AP virions were determined as described in the text.
The number of particles in each window of 0.2 × 108
Da is shown on the ordinate, and the measured masses of particles are
on the abcissa.
|
|
Given the assumption that all virions contain identical ratios of their
components
i.e., Gag, Pol, Env, host proteins, RNA, and lipid
it is
possible to calculate the stoichiometry of Gag protein. These
calculations are based on several measurements carried out previously
or on the following assumptions. First, we assume that 95% of
radioactive proteins (Fig. 1) and also of lipids are in bona fide
virions, with the remaining 5% representing contaminating
microvesicles. This assumption is obviously somewhat arbitrary and is
based in part on the STEM pictures themselves, which show a scattering
of smaller particulate matter that might be microvesicles. Second, we
take the lipid content for RSV to be 31%, which is the average of
several determinations (range ± 4%) of the percentage of dry
mass reported by Quigley et al. (28). In this and other,
similar studies, lipid was defined as the percentage of dry mass of the
preparation that could be extracted into chloroform-methanol. Virus
purity is not a very critical factor in interpreting these data if any
contaminating material has the same protein/lipid ratio, as might be
expected from the purification by equilibrium sedimentation. It is
known that even extensively purified retroviruses can be contaminated with microvesicles that are associated with cellular proteins (20). Third, we take the RNA content to be 2.3% for RCASBP
and 3% for RCASBP-AP. These values are based on the assumption that each particle of RCASBP or RCASBP-AP contains two copies of the 7.4- or
9.3-kB genomic RNA, respectively, plus tRNA and other small RNAs
comprising an additional 30% of the genomic RNA by mass (9, 10,
31, 32), equaling about 3.5 kb of tRNA. Fourth, using the average
PhosphorImager values for SU, i.e., 4% of total radioactive protein,
and assuming an equimolar amount of TM, we estimate that the Env
polypeptides account for 6% of the radioactive virion protein. Given
the more than a dozen Env N-linked glycosylation sites, carbohydrate
then should comprise about 4% of the virion protein mass, or about 3%
of the total mass.
Finally, we take the sum of Gag proteins to represent 73% of the total
protein in bona fide virions, slightly less than the total amount of
label migrating with CA or more rapidly. We chose to use a method of
calculating this value that is based on PhosphorImager quantitation of
the CA band alone, since this is the most cleanly resolved Gag protein
and since choosing a single, narrowly defined band obviates the
need to make any assumptions about cellular proteins that may migrate
in the lower part of the gel. [14C]glycine-labeled
CA and [14C]leucine-labeled CA comprised 16.6 and 26.7% of the total radioactivity in the lane of the gel,
respectively, i.e., 17.5 and 28.1% of the label in bona fide virions
according to the assumption about virus purity. Given that CA has 17 of
the 74 Gag glycine residues and 24 of the 60 Gag leucine residues, and
assuming that Gag proteins are equimolar, all of the Gag proteins
together thus must represent 76% of the glycine-labeled virus and 70%
of the leucine-labeled virus, giving an average value of 73%. This
calculated percentage of protein that is Gag is consistent with
previous analyses of avian retrovirus polypeptides by SDS-PAGE and by
gel filtration in guanidine hydrochloride, although in some of these
earlier experiments the amount of Gag was as low as 65 to 70%
(12, 35, 38). On the other hand, some published SDS-PAGE
profiles of [35S]methionine-labeled RSV as well as of
other retroviruses appear to indicate that Gag constitutes more than
80% of the total radioactive protein. However, visual estimates of
this type are misleading. Furthermore, labeling with this isotope is
rarely done under steady-state conditions, and hence the results
generally reflect an overestimation of abundance for proteins that are
turned over rapidly, like Gag itself.
Based on these several assumptions and measurements, the mean mass of
2.5 × 108 Da for the two RSV viruses then corresponds
to about 1,500 Gag molecules per virion. According to the distributions
shown in Fig. 3, 40% of the virions in RCASBP and 60% of the virions
in RCASBP-AP have 1,300 to 1,700 Gag molecules; the remainder of the
virions fall outside of those limits.
Discussion.
The STEM data presented here provide the first
direct measurement of the mass of a retrovirus, which leads in turn to
an estimate for the average number of each Gag protein in a virion. The
accuracy of each virion mass measurement does not significantly affect this number, since with the internal calibrations that are used routinely the STEM data are within ±5%. Rather, the major factors affecting accuracy are the uncertainties in purity, in lipid content, and in content of proteins other than Gag. The purity estimate of 95%
is a nominal value. Unlike HIV (20), RSV has never been submitted to a direct analysis for microvesicle
contamination. However, clearly the STEM pictures show
evidence of particulate material smaller than virus particles. Given
the agreement in the lipid data for RSV (28) and the closely
related AMV (3, 4), the correct lipid content is likely to
be within 5% of the given value (i.e., between 26 and 36% of the
total mass). As an example, if RSV contained 36% instead of 31%
lipid, the calculated average number of each of the Gag proteins would
drop from 1,500 to 1,400. The percentage of protein that is Gag also is
probably within 5% of being correct, given the abundance of values in
the literature that cluster around this number. If Gag proteins
accounted for 78% of virion protein mass instead of 73%, the
calculated average number of each Gag protein would rise to about
1,600.
In interpreting the observed heterogeneity in RSV particle mass, we
make the simplifying assumption that in particles differing in mass,
the ratios of Gag, lipid, and other proteins are identical. This
assumption is difficult to test, and while it is likely to hold for
Gag/lipid ratios, it may not hold for Gag/Env ratios. Since
retroviruses do not need Env protein to bud, virions budding from one
part of the plasma membrane plausibly could pick up more Env protein
than those budding from another. Also, SU could be lost differentially
from some particles by shedding. However, the observed mass
heterogeneity is much too large to be explained by variations in Env
levels. If the SU that comprised about 4% of the total radioactive
protein in the lane on the gel was unevenly distributed, so that the
number was 2% for some virions and 6% for others, the virion mass
would differ by only about 4%, far less than the standard deviation in
observed masses. Furthermore, and more importantly, virion diameters
measured by cryo-EM for the same RCASBP preparation used in our
analyses showed a standard deviation of ±10% (17a),
consistent with the size heterogeneity described for MLV
(40). Assuming that the amount of Gag protein and the amount
of lipid in a virion increase as the square of the virion diameter
(since both form two-dimensional shells), the 10% standard deviation
of diameters implies a ca. 20% standard deviation in the mass of Gag
plus lipid, roughly consistent with the standard deviation of 25% that
we observed.
Since proteolytic cleavage occurs late in budding, it is widely
believed that the mature Gag proteins are equimolar in virions, although this assumption has never been tested critically. Because of
the comigration of some Gag proteins upon SDS-PAGE as well as upon
subjection to the previously used method of high-resolution gel
filtration in guanidine, it is difficult to exactly quantify the
several Gag proteins independently. This problem is exacerbated by the
propensity of the p10 protein to leach out of gels even after fixation
(21) and by the nonuniform or incomplete cleavage of MA.
Depending on the strain of virus and on the virus preparation, MA may
carry C-terminal extensions including p2a, p2b, or p10 or may be
cleaved by a host cell protease to yield a polypeptide shorter than MA
(22, 24, 33). Thus, it is possible that the apparent modest
underrepresentation of MA in virions (Fig. 1), which was already
observed many years ago (12, 35, 38), is simply due to
alternatively processed forms of this polypeptide that migrate
differently on SDS-polyacrylamide gels. However, the possibility that
late in budding, after some or all of the mature MA has been generated
by proteolysis, some of the MA molecules are resorbed back into the
cell has not been rigorously ruled out. In that case, the concept of
the number of Gag proteins per virion would have to be reinterpreted.
One of the motivations of our experiments was to examine the
possibility that size variation in retroviruses is due to differences in RNA incorporation. That RNA may play a structural role in
retroviruses is suggested by in vitro assembly studies; formation of
spherical virus-like particles in vitro, from purified HIV-1 and RSV
Gag proteins expressed in Escherichia coli, is dependent on
the presence of nucleic acid (4a, 5, 6, 16a). Furthermore,
the mass ratio of RNA to Gag protein in such particles is constant,
regardless of the molecular size of the RNA, implying that the RNA is
fully covered by the NC domain of Gag (41). Thus, we
expected RCASBP-AP virus to incorporate about 20% more Gag molecules
than RCASBP, because of the larger genome size of the former. In fact,
this expectation was not fulfilled. However, there appeared to be a distinctly greater heterogeneity of mass in the virus with the smaller
genome. We have no convincing hypothesis to explain this difference.
Two models could account for the similarity in the masses of the two
viruses. In one, the smaller genomic mass in RCASBP is compensated by
the incorporation of relatively more tRNA. In the other, there is no
obligatory stoichiometric relationship in vivo between the RNA and
amount of Gag protein incorporated into a virion. These possibilities
could be addressed directly by a careful analysis of RNA content in
retroviruses that have different genome sizes, including viruses that
have no packageable genome.
 |
ACKNOWLEDGMENTS |
We thank Steve Hughes and Mark Federspiel for the molecular clones
of RSV and Richard Kingston and Michael Rossmann for communicating results on the cryo-EM of RSV particles.
This work was supported by U.S. Public Health Service grant CA20081 to
V.M.V. The Brookhaven National Laboratory STEM facility is an
NIH-supported resource center (NIH P41-RR01777), with additional support provided by the Department of Energy and the Office of Biological and Environmental Research.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of
Molecular Biology and Genetics, Biotechnology Building, Cornell
University, Ithaca, NY 14853. Phone: (607) 255-2443. Fax: (607)
255-2428. E-mail: vmv1{at}cornell.edu.
 |
REFERENCES |
| 1.
|
Aloia, R. C.,
H. Tian, and F. C. Jensen.
1993.
Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.
Proc. Natl. Acad. Sci. USA
90:5181-5185[Abstract/Free Full Text].
|
| 2.
|
Arthur, L. O.,
J. W. Bess, Jr.,
R. C. Sowder II,
R. E. Benveniste,
D. L. Mann,
J. C. Chermann, and L. E. Henderson.
1992.
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.
Science
258:1935-1938[Abstract/Free Full Text].
|
| 3.
|
Beard, J. W.
1963.
Avian virus growth and their etiologic agents.
Adv. Cancer Res.
7:1-126.
|
| 4.
|
Bonar, R. A., and J. W. Beard.
1959.
Virus of avian myeloblastosis. XII. Chemical constitution.
J. Natl. Cancer Inst.
23:183-195.
|
| 4a.
| Campbell, S., and A. Rein. Personal communication.
|
| 5.
|
Campbell, S., and V. M. Vogt.
1995.
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.
J. Virol.
69:6487-6497[Abstract].
|
| 6.
|
Campbell, S., and V. M. Vogt.
1997.
In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
J. Virol.
71:4425-4435[Abstract].
|
| 7.
|
Duesberg, P. H.,
H. L. Robinson,
W. S. Robinson,
R. J. Huebner, and H. C. Turner.
1968.
Proteins of Rous sarcoma virus.
Virology
36:73-86[Medline].
|
| 8.
|
Duesberg, P. H.,
G. S. Martin, and P. K. Vogt.
1970.
Glycoprotein components of avian and murine RNA tumor viruses.
Virology
41:631-646[Medline].
|
| 9.
|
Erikson, R. L.
1969.
Studies on the RNA from avian myeloblastosis virus.
Virology
37:124-131[Medline].
|
| 10.
|
Faras, A. J.,
A. C. Garapin,
W. E. Levinson,
J. M. Bishop, and H. M. Goodman.
1973.
Characterization of the low-molecular-weight RNAs associated with the 70S RNA of Rous sarcoma virus.
J. Virol.
12:334-342[Abstract/Free Full Text].
|
| 10a.
| Federspiel, M. Personal communication.
|
| 11.
|
Fekete, D. M., and C. L. Cepko.
1993.
Replication-competent retroviral vectors encoding alkaline phosphatase reveal spatial restriction of viral gene expression/transduction in the chick embryo.
Mol. Cell. Biol.
13:2604-2613[Abstract/Free Full Text].
|
| 12.
|
Fleissner, E.
1971.
Chromatographic separation and antigenic analysis of proteins of the oncornaviruses. I. Avian leukemia-sarcoma viruses.
J. Virol.
8:778-785[Abstract/Free Full Text].
|
| 13.
|
Franke, E. K.,
H. E. H. Yuan, and J. Luban.
1994.
Specific incorporation of cyclophilin A into HIV-1 virions.
Nature
372:359-362[Medline].
|
| 14.
|
Fuller, S. D.,
T. Wilk,
B. E. Gowen,
H.-G. Kräusslich, and V. M. Vogt.
1997.
Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle.
Curr. Biol.
7:729-738[Medline].
|
| 15.
|
Garnier, L.,
L. Ratner,
B. Rovinski,
S.-X. Cao, and J. W. Wills.
1998.
Particle size determinants in the human immunodeficiency virus type 1 Gag protein.
J. Virol.
72:4667-4677[Abstract/Free Full Text].
|
| 16.
|
Garnier, L.,
L. J. Parent,
B. Rovinski,
S.-X. Cao, and J. W. Wills.
1999.
Identification of retroviral late domains as determinants of particle size.
J. Virol.
73:2309-2320[Abstract/Free Full Text].
|
| 16a.
| Gross, I., and H.-G. Kräuslich.
Personal communication.
|
| 17.
|
Jacks, T., and H. E. Varmus.
1985.
Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting.
Science
230:1237-1242[Abstract/Free Full Text].
|
| 17a.
| Kingston, R., and M. Rossmann. Personal
communication.
|
| 18.
|
Krishna, N. K.,
S. Campbell,
V. M. Vogt, and J. W. Wills.
1998.
Genetic determinants of Rous sarcoma virus particle size.
J. Virol.
72:564-577[Abstract/Free Full Text].
|
| 19.
|
Ott, D. E.,
L. V. Coren,
D. G. Johnson,
R. C. Sowder,
L. O. Arthur, and L. E. Henderson.
1995.
Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.
AIDS Res. Hum. Retroviruses
11:1003-1006[Medline].
|
| 20.
|
Ott, D. E.,
L. V. Coren,
B. P. Kane,
L. K. Busch,
D. G. Johnson,
R. C. Sowder II,
E. N. Chertova,
L. O. Arthur, and L. E. Henderson.
1996.
Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.
J. Virol.
70:7734-7743[Abstract].
|
| 21.
|
Pepinsky, R. B., and V. M. Vogt.
1983.
Purification and properties of a fifth major viral gag protein from avian sarcoma and leukemia viruses.
J. Virol.
45:648-658[Abstract/Free Full Text].
|
| 22.
|
Pepinsky, R. B.,
R. J. Mattaliano, and V. M. Vogt.
1986.
Structure and processing of the p2 region of avian sarcoma and leukemia virus gag precursor polyproteins.
J. Virol.
58:50-58[Abstract/Free Full Text].
|
| 23.
|
Pepinsky, R. B.,
I. A. Papayannopoulos,
E. P. Chow,
N. K. Krishna,
R. C. Craven, and V. M. Vogt.
1995.
Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses.
J. Virol.
69:6430-6438[Abstract].
|
| 24.
|
Pepinsky, R. B.,
I. A. Papayannopoulos,
S. Campbell, and V. M. Vogt.
1996.
Analysis of Rous sarcoma virus Gag proteins by mass spectrometry indicates trimming by host exopeptidase.
J. Virol.
70:3313-3318[Abstract].
|
| 25.
|
Petropoulos, C. J., and S. H. Hughes.
1991.
Replication-competent retrovirus vectors for the transfer and expression of gene cassettes in avian cells.
J. Virol.
65:3728-3737[Abstract/Free Full Text].
|
| 26.
|
Petropoulos, C. J.,
W. Payne,
D. W. Salter, and S. H. Hughes.
1992.
Using avian retroviral vectors for gene transfer.
J. Virol.
66:3391-3397[Abstract/Free Full Text].
|
| 27.
|
Putterman, D.,
R. B. Pepinsky, and V. M. Vogt.
1990.
Ubiquitin in avian sarcoma and leukemia virus particles.
Virology
176:633-637[Medline].
|
| 28.
|
Quigley, J. P.,
D. B. Rifkin, and E. Reich.
1971.
Phospholipid composition of Rous sarcoma virus, host cell membranes, and other enveloped RNA viruses.
Virology
46:106-116[Medline].
|
| 29.
|
Rey, O.,
J. Canon, and P. Krogstad.
1996.
HIV-1 gag protein associates with F-actin present in microfilaments.
Virology
220:530-534[Medline].
|
| 30.
|
Rifkin, D. B., and R. W. Compans.
1971.
Identification of the spike proteins of Rous sarcoma virus.
Virology
46:485-489[Medline].
|
| 31.
|
Robinson, W. S.,
H. L. Robinson, and P. H. Duesberg.
1967.
Tumor virus RNAs.
Proc. Natl. Acad. Sci. USA
58:825-834[Free Full Text].
|
| 32.
|
Sawyer, R. C., and J. E. Dahlberg.
1973.
Small RNAs of Rous sarcoma virus: characterization by two-dimensional polyacrylamide gel electrophoresis and fingerprint analysis.
J. Virol.
12:1226-1237[Abstract/Free Full Text].
|
| 33.
|
Shealy, D. J.,
A. G. Mosser, and R. R. Rueckert.
1980.
Novel p19-related protein in Rous-associated virus type 61: implications for avian gag gene order.
J. Virol.
34:431-437[Abstract/Free Full Text].
|
| 34.
|
Stewart, L.,
G. Schatz, and V. M. Vogt.
1990.
Properties of avian retrovirus particles defective in viral protease.
J. Virol.
64:5076-5092[Abstract/Free Full Text].
|
| 35.
|
Stromberg, K.,
N. E. Hurley,
N. L. Davis,
R. R. Rueckert, and E. Fleissner.
1974.
Structural studies of avian myeloblastosis virus: comparison of polypeptides in virion and core component by dodecyl sulfate-polyacrylamide gel electrophoresis.
J. Virol.
13:513-528[Abstract/Free Full Text].
|
| 36.
|
Thali, M.,
A. Bukovsky,
E. Kondo,
B. Rosenwirth,
C. T. Walsh,
J. Sodroski, and H. G. Göttlinger.
1994.
Functional association of cyclophilin A with HIV-1 virions.
Nature
372:363-365[Medline].
|
| 37.
|
Thomas, D.,
W. W. Newcomb,
J. C. Brown,
J. S. Wall,
J. F. Hainfeld,
B. L. Trus, and A. C. Steven.
1985.
Mass and molecular composition of vesicular stomatitis virus: a scanning transmission electron microscopy analysis.
J. Virol.
54:598-607[Abstract/Free Full Text].
|
| 38.
|
Vogt, V. M.,
R. Eisenman, and H. Diggelmann.
1975.
Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide.
J. Mol. Biol.
96:471-493[Medline].
|
| 39.
|
Wall, J. S.,
J. F. Hainfeld, and M. N. Simon.
1998.
Scanning transmission electron microscopy (STEM) of nuclear structures.
Methods Cell Biol.
53:139-166[Medline].
|
| 40.
|
Yeager, M.,
E. M. Wilson-Kubalek,
S. G. Weiner,
P. O. Brown, and A. Rein.
1998.
Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechanisms.
Proc. Natl. Acad. Sci. USA
95:7299-7304[Abstract/Free Full Text].
|
| 41.
| Yu, F., and V. M. Vogt. Unpublished data.
|
Journal of Virology, August 1999, p. 7050-7055, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lee, E.-G., Kuppers, D., Horn, M., Roy, J., May, C., Linial, M. L.
(2008). A Premature Termination Codon Mutation at the C Terminus of Foamy Virus Gag Downregulates the Levels of Spliced pol mRNA. J. Virol.
82: 1656-1664
[Abstract]
[Full Text]
-
Chertova, E., Chertov, O., Coren, L. V., Roser, J. D., Trubey, C. M., Bess, J. W. Jr., Sowder, R. C. II, Barsov, E., Hood, B. L., Fisher, R. J., Nagashima, K., Conrads, T. P., Veenstra, T. D., Lifson, J. D., Ott, D. E.
(2006). Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.. J. Virol.
80: 9039-9052
[Abstract]
[Full Text]
-
Saad, J. S., Miller, J., Tai, J., Kim, A., Ghanam, R. H., Summers, M. F.
(2006). From the Cover: Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. USA
103: 11364-11369
[Abstract]
[Full Text]
-
Ulbrich, P., Haubova, S., Nermut, M. V., Hunter, E., Rumlova, M., Ruml, T.
(2006). Distinct Roles for Nucleic Acid in In Vitro Assembly of Purified Mason-Pfizer Monkey Virus CANC Proteins. J. Virol.
80: 7089-7099
[Abstract]
[Full Text]
-
Dalton, A. K., Murray, P. S., Murray, D., Vogt, V. M.
(2005). Biochemical Characterization of Rous Sarcoma Virus MA Protein Interaction with Membranes. J. Virol.
79: 6227-6238
[Abstract]
[Full Text]
-
Yuste, E., Reeves, J. D., Doms, R. W., Desrosiers, R. C.
(2004). Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity. J. Virol.
78: 6775-6785
[Abstract]
[Full Text]
-
Boyer, P. L., Stenbak, C. R., Clark, P. K., Linial, M. L., Hughes, S. H.
(2004). Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase. J. Virol.
78: 6112-6121
[Abstract]
[Full Text]
-
Voronin, Y. A., Pathak, V. K.
(2004). Frequent Dual Initiation in Human Immunodeficiency Virus-Based Vectors Containing Two Primer-Binding Sites: a Quantitative In Vivo Assay for Function of Initiation Complexes. J. Virol.
78: 5402-5413
[Abstract]
[Full Text]
-
Larson, D. R., Ma, Y. M., Vogt, V. M., Webb, W. W.
(2003). Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy. J. Cell Biol.
162: 1233-1244
[Abstract]
[Full Text]
-
Callahan, E. M., Wills, J. W.
(2003). Link between Genome Packaging and Rate of Budding for Rous Sarcoma Virus. J. Virol.
77: 9388-9398
[Abstract]
[Full Text]
-
Teysset, L., Dang, V.-D., Kim, M. K., Levin, H. L.
(2003). A Long Terminal Repeat-Containing Retrotransposon of Schizosaccharomyces pombe Expresses a Gag-Like Protein That Assembles into Virus-Like Particles Which Mediate Reverse Transcription. J. Virol.
77: 5451-5463
[Abstract]
[Full Text]
-
Johnson, M. C., Scobie, H. M., Ma, Y. M., Vogt, V. M.
(2002). Nucleic Acid-Independent Retrovirus Assembly Can Be Driven by Dimerization. J. Virol.
76: 11177-11185
[Abstract]
[Full Text]
-
Rinke, C. S., Boyer, P. L., Sullivan, M. D., Hughes, S. H., Linial, M. L.
(2002). Mutation of the Catalytic Domain of the Foamy Virus Reverse Transcriptase Leads to Loss of Processivity and Infectivity. J. Virol.
76: 7560-7570
[Abstract]
[Full Text]
-
Lanman, J., Sexton, J., Sakalian, M., Prevelige, P. E. Jr.
(2002). Kinetic Analysis of the Role of Intersubunit Interactions in Human Immunodeficiency Virus Type 1 Capsid Protein Assembly In Vitro. J. Virol.
76: 6900-6908
[Abstract]
[Full Text]
-
Chertova, E., Bess, J. W. Jr., Crise, B. J., Sowder II, R. C., Schaden, T. M., Hilburn, J. M., Hoxie, J. A., Benveniste, R. E., Lifson, J. D., Henderson, L. E., Arthur, L. O.
(2002). Envelope Glycoprotein Incorporation, Not Shedding of Surface Envelope Glycoprotein (gp120/SU), Is the Primary Determinant of SU Content of Purified Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus. J. Virol.
76: 5315-5325
[Abstract]
[Full Text]
-
Ma, Y. M., Vogt, V. M.
(2002). Rous Sarcoma Virus Gag Protein-Oligonucleotide Interaction Suggests a Critical Role for Protein Dimer Formation in Assembly. J. Virol.
76: 5452-5462
[Abstract]
[Full Text]
-
Nermut, M. V., Bron, P., Thomas, D., Rumlova, M., Ruml, T., Hunter, E.
(2002). Molecular Organization of Mason-Pfizer Monkey Virus Capsids Assembled from Gag Polyprotein in Escherichia coli. J. Virol.
76: 4321-4330
[Abstract]
[Full Text]
-
Patnaik, A., Chau, V., Li, F., Montelaro, R. C., Wills, J. W.
(2002). Budding of Equine Infectious Anemia Virus Is Insensitive to Proteasome Inhibitors. J. Virol.
76: 2641-2647
[Abstract]
[Full Text]
-
Ott, D. E., Coren, L. V., Sowder, R. C. II, Adams, J., Nagashima, K., Schubert, U.
(2002). Equine Infectious Anemia Virus and the Ubiquitin-Proteasome System. J. Virol.
76: 3038-3044
[Abstract]
[Full Text]
-
Tang, S., Murakami, T., Agresta, B. E., Campbell, S., Freed, E. O., Levin, J. G.
(2001). Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants That Exhibit Aberrant Core Morphology and Are Blocked in Initiation of Reverse Transcription in Infected Cells. J. Virol.
75: 9357-9366
[Abstract]
[Full Text]
-
Parker, S. D., Wall, J. S., Hunter, E.
(2001). Analysis of Mason-Pfizer Monkey Virus Gag Particles by Scanning Transmission Electron Microscopy. J. Virol.
75: 9543-9548
[Abstract]
[Full Text]
-
Krishna, N. K., Wills, J. W.
(2001). Insertion of Capsid Proteins from Nonenveloped Viruses into the Retroviral Budding Pathway. J. Virol.
75: 6527-6536
[Abstract]
[Full Text]
-
Johnson, M. C., Scobie, H. M., Vogt, V. M.
(2001). PR Domain of Rous Sarcoma Virus Gag Causes an Assembly/Budding Defect in Insect Cells. J. Virol.
75: 4407-4412
[Abstract]
[Full Text]
-
Muriaux, D., Mirro, J., Harvin, D., Rein, A.
(2001). RNA is a structural element in retrovirus particles. Proc. Natl. Acad. Sci. USA
98: 5246-5251
[Abstract]
[Full Text]
-
Yu, F., Joshi, S. M., Ma, Y. M., Kingston, R. L., Simon, M. N., Vogt, V. M.
(2001). Characterization of Rous Sarcoma Virus Gag Particles Assembled In Vitro. J. Virol.
75: 2753-2764
[Abstract]
[Full Text]
-
Patnaik, A., Chau, V., Wills, J. W.
(2000). Ubiquitin is part of the retrovirus budding machinery. Proc. Natl. Acad. Sci. USA
97: 13069-13074
[Abstract]
[Full Text]
-
O'Doherty, U., Swiggard, W. J., Malim, M. H.
(2000). Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding. J. Virol.
74: 10074-10080
[Abstract]
[Full Text]
-
Joshi, S. M., Vogt, V. M.
(2000). Role of the Rous Sarcoma Virus p10 Domain in Shape Determination of Gag Virus-Like Particles Assembled In Vitro and within Escherichia coli. J. Virol.
74: 10260-10268
[Abstract]
[Full Text]
-
Müller, B., Tessmer, U., Schubert, U., Kräusslich, H.-G.
(2000). Human Immunodeficiency Virus Type 1 Vpr Protein Is Incorporated into the Virion in Significantly Smaller Amounts than Gag and Is Phosphorylated in Infected Cells. J. Virol.
74: 9727-9731
[Abstract]
[Full Text]
-
Cimarelli, A., Luban, J.
(2000). Human Immunodeficiency Virus Type 1 Virion Density Is Not Determined by Nucleocapsid Basic Residues. J. Virol.
74: 6734-6740
[Abstract]
[Full Text]
-
Welker, R., Hohenberg, H., Tessmer, U., Huckhagel, C., Kräusslich, H.-G.
(2000). Biochemical and Structural Analysis of Isolated Mature Cores of Human Immunodeficiency Virus Type 1. J. Virol.
74: 1168-1177
[Abstract]
[Full Text]
-
Baldwin, D. N., Linial, M. L.
(1999). Proteolytic Activity, the Carboxy Terminus of Gag, and the Primer Binding Site Are Not Required for Pol Incorporation into Foamy Virus Particles. J. Virol.
73: 6387-6393
[Abstract]
[Full Text]